Trubion facility adds Dyax’ phage library to indentify therapeutic leads.

Dyax and Trubion Pharmaceuticals have prolonged its existing research agreement, which covers protein therapeutics and diagnostics discovery.

In addition to the ongoing multiple-target funded research project, Dyax will now transfer its phage library to Trubion’s facility for use in identifying therapeutic leads to additional targets. This will enhanceTrubion’s ability to rapidly design and develop product candidates for a range of disease targets.

Previous articleGenetic Variation Associated with Aggressive Prostate Cancer
Next articleBioSeek Will Apply Screening Capabilities to Amylin’s Polypeptide Library